Nothing of import, but on the radar screen. From his Biotech Mailbag column released today (note: OGXI isn't the only company referenced):
"To select the next test cases for the Feuerstein-Ratain Rule, I ran a screen using BioMedTracker for companies with cancer drugs in phase III studies expected to announce top-line results within the next six months.
"Remember, the F-R Rule tries to predict the outcome of phase III studies of cancer drugs based on the market cap of the company conducting the study four months prior to the expected results.
"Here's what I came up with:
"Oncogenex Pharmaceuticals (OGXI_): The "Synergy" study of custirsen in combination with docetaxel in first-line prostate cancer patients should have survival results ready in mid-2014. That timeline makes Oncogenex a bit early for assessment by the F-R Rule but keep it in mind."
We need "Good News" and we need it NOW!
Hopefully, sooner than later. I mean there's worse things going on in the world right now, but this is a bit frustrating!
We'll know more with the earnings call.